Kim Forest Enterprise Past Earnings Performance
Past criteria checks 0/6
Kim Forest Enterprise has been growing earnings at an average annual rate of 9.2%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 18.7% per year.
Key information
9.2%
Earnings growth rate
14.5%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 18.7% |
| Return on equity | -17.7% |
| Net Margin | -24.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Kim Forest Enterprise makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 415 | -102 | 178 | 27 |
| 30 Sep 23 | 388 | -98 | 168 | 24 |
| 30 Jun 23 | 425 | -83 | 176 | 22 |
| 31 Mar 23 | 548 | -20 | 178 | 21 |
| 31 Dec 22 | 671 | 42 | 168 | 19 |
| 30 Sep 22 | 744 | 104 | 172 | 19 |
| 30 Jun 22 | 783 | 143 | 159 | 20 |
| 31 Mar 22 | 692 | 116 | 142 | 21 |
| 31 Dec 21 | 601 | 89 | 125 | 22 |
| 30 Sep 21 | 516 | 60 | 110 | 22 |
| 30 Jun 21 | 431 | 30 | 96 | 23 |
| 31 Mar 21 | 367 | 2 | 91 | 25 |
| 31 Dec 20 | 303 | -26 | 87 | 27 |
| 30 Sep 20 | 285 | -29 | 80 | 26 |
| 30 Jun 20 | 267 | -33 | 72 | 25 |
| 31 Mar 20 | 269 | -32 | 73 | 22 |
| 31 Dec 19 | 271 | -32 | 73 | 19 |
| 30 Sep 19 | 261 | -34 | 73 | 19 |
| 30 Jun 19 | 252 | -37 | 73 | 18 |
| 31 Mar 19 | 242 | -34 | 70 | 17 |
| 31 Dec 18 | 232 | -31 | 67 | 16 |
| 30 Sep 18 | 229 | -21 | 66 | 12 |
| 30 Jun 18 | 226 | -12 | 64 | 8 |
| 31 Mar 18 | 245 | -1 | 60 | 6 |
| 31 Dec 17 | 264 | 9 | 55 | 5 |
| 30 Sep 17 | 280 | 12 | 51 | 6 |
| 30 Jun 17 | 297 | 16 | 48 | 6 |
| 31 Mar 17 | 279 | 13 | 46 | 6 |
| 31 Dec 16 | 262 | 10 | 43 | 6 |
| 31 Dec 15 | 268 | 10 | 38 | 5 |
| 31 Dec 14 | 188 | 2 | 39 | 0 |
Quality Earnings: 6645 is currently unprofitable.
Growing Profit Margin: 6645 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6645 is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.
Accelerating Growth: Unable to compare 6645's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6645 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6645 has a negative Return on Equity (-17.73%), as it is currently unprofitable.